A1C

There are 10 papers on A1C in aging research: 2 trials and 6 observational studies in people, 2 reviews.

Biomarker

10 papers study it13 findings

2 new papers in 30 daysSee all 10 papers on A1C

“Greater A1C lowering and weight loss was observed in patients without prior GLP1-RA treatment compared to those switched to tirzepatide from GLP1-RA.”
Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitusDiabetes, obesity & metabolism2024doi:10.1111/dom.15934
  • Human trial2
  • Humans6

Interventions

6

Tirzepatide

downin humans4

4 studies
  1. Tirzepatide is linked with lower A1C in humans (added to concomitant insulin therapy in patients with type 2 diabetes).

    Humansadded to concomitant insulin therapy in patients with type 2 diabetesn = 135

  2. Tirzepatide is linked with lower A1C in humans (mean reduction 1.02 ± 1.48%).

    Humansmedian 10.4 monthsn = 612

  3. Tirzepatide decreases A1C in humans (lowered by 1.7-2.4% from baseline).

    Review

  4. Tirzepatide decreases A1C in humans.

    Review

More on Tirzepatide

GLP-1 receptor agonists

downin reviews1

1 study
  1. GLP-1 receptor agonists decrease A1C (obesity and type 2 diabetes) (A1c levels below 5.7%).

    Reviewobesity and type 2 diabetes

More on GLP-1 receptor agonists

Continuous glucose monitoring

downin humans1−0.4% greater reduction

1 study
  1. Continuous glucose monitoring is linked with lower A1C in humans (compared with non-CGM users) (0.4% greater reduction).

    Humanscompared with non-CGM users

More on Continuous glucose monitoring

Physical activity

no changein humans1

1 study
  1. Physical activity was not clearly linked with A1C in humans (prediabetes and overweight/obesity; adjusted models; reference <75 min/week) (No significant association across A1C reduction thresholds ≥0.1% to ≥0.4%).

    Humansprediabetes and overweight/obesity; adjusted models; reference <75 min/weeksix 75-min weekly increments, ranging from <75 to >375 min12 monthsn = 209

More on Physical activity

Sulfonylureas

downin humans1

1 study
  1. Sulfonylureas are linked with lower A1C in humans (sulfonylurea alone in young-onset type 2 diabetes; usual-onset showed an increase) (-0.08% (young-onset) vs +0.06% (usual-onset)).

    Humanssulfonylurea alone in young-onset type 2 diabetes; usual-onset showed an increase

More on Sulfonylureas

Metformin

downin humans1

1 study
  1. Metformin is linked with lower A1C in young-onset type 2 diabetes, compared with usual-onset (-0.15% (young-onset) vs -0.17% (usual-onset)).

    Humansin young-onset type 2 diabetes, compared with usual-onset

More on Metformin

Associations

4

Spontaneous alpha power

downin humans1

1 study
  1. A1C is associated with spontaneous alpha power in humans (cognitively normal aging adults).

    Humanscognitively normal aging adultsinferior frontal and temporal cortexn = 43

More on Spontaneous alpha power

Spontaneous delta power

downin humans1

1 study
  1. A1C is associated with spontaneous delta power in humans (biomarker-positive participants on the Alzheimer’s disease spectrum).

    Humansbiomarker-positive participants on the Alzheimer’s disease spectrumfrontotemporal and inferior parietal cortexn = 37

More on Spontaneous delta power

Weight loss

downin humans1OR 6.36–9.49

1 study
  1. Weight loss is associated with A1C in humans (prediabetes and overweight/obesity; compared with no weight loss) (OR range 6.36–9.49 for A1C reductions ≥0.1% to ≥0.4%).

    Humansprediabetes and overweight/obesity; compared with no weight loss>5% weight loss12 monthsn = 209

More on Weight loss

Tirzepatide

downin humans1

1 study
  1. Tirzepatide is associated with A1C in humans (greater in GLP1-RA-naive patients than in patients switched from GLP1-RA).

    Humansgreater in GLP1-RA-naive patients than in patients switched from GLP1-RA

More on Tirzepatide

Funding

3 grants since 2018

National Institute of Diabetes and Digestive and Kidney Diseases$1.3MUS Department of Veterans Affairs

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 1May 2026: 0Jun 2026: 1Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 24 papers in 12 months